Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Base rate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    303 result(s) found for: Base rate. Displaying page 7 of 16.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2012-001410-41 Sponsor Protocol Number: IRST172.02 Start Date*: 2013-05-30
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastati...
    Medical condition: metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008337-11 Sponsor Protocol Number: A3921046 Start Date*: 2009-05-27
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND DMARDS
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) GB (Completed) FI (Completed) PL (Completed) DK (Completed) SK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001236-28 Sponsor Protocol Number: R39_21_01 Start Date*: 2023-01-13
    Sponsor Name:Fidia Farmaceutici S.p.A.
    Full Title: A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCG-unresponsive Carcinoma in Si...
    Medical condition: BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007400 Carcinoma in situ of the bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011237-27 Sponsor Protocol Number: CAIN457C2303 Start Date*: 2009-10-15
    Sponsor Name:Novartis Pharma Services Ag
    Full Title: A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated ...
    Medical condition: Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FR (Completed) DE (Completed) AT (Prematurely Ended) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001790-86 Sponsor Protocol Number: PIX306 Start Date*: 2012-12-24
    Sponsor Name:CTI Biopharma, Corp.
    Full Title: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or a...
    Medical condition: Treatment of Patients with Aggressive B-cell Non-Hodgkin Lymphoma , who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    19.1 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) HU (Completed) IT (Completed) CZ (Completed) DK (Prematurely Ended) BG (Prematurely Ended) PL (Completed) BE (Completed) AT (Completed) SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-001048-73 Sponsor Protocol Number: BAY41-6551/13084 Start Date*: 2013-07-25
    Sponsor Name:Bayer AG
    Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Pati...
    Medical condition: Gram-negative pneumonia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10035701 Pneumonia gram-negative bacterial NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004551-43 Sponsor Protocol Number: CS-BM32-004 Start Date*: 2016-01-29
    Sponsor Name:Biomay AG
    Full Title: Study to evaluate the effect of different pre-seasonal BM32 dosing schedules on the induction of a protective allergen-specific IgG Immune response
    Medical condition: Grass pollen allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004361-32 Sponsor Protocol Number: KKS-166 Start Date*: 2013-02-26
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid A prospective multi-centre randomised double-blind placebo-controlled pilot study
    Medical condition: Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal p...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001565-25 Sponsor Protocol Number: MR311-3504 Start Date*: 2017-11-21
    Sponsor Name:MUNDIPHARMA PHARMACEUTICALS SRL
    Full Title: Efficacy and safety of methoxyflurane vaporized (PENTHROX®) in the treatment of acute trauma pain in pre-hospital setting and in the emergency department in Italy: a multicentre, randomized, contro...
    Medical condition: Acute trauma pain
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10072132 Fracture pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003630-18 Sponsor Protocol Number: ICLA-09-CSI2 Start Date*: 2006-01-31
    Sponsor Name:Arpida AG
    Full Title: Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections
    Medical condition: Complicated skin and skin structure infections are predominantly caused by the following Gram-positive pathogens: Staphylococcus aureus, including methicillin-resistant strains, beta hemolytic stre...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040786 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed) DE (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001938-14 Sponsor Protocol Number: 60711868 Start Date*: 2008-03-31
    Sponsor Name:AVAPO RICERCHE - VENEZIA
    Full Title: Neoadjuvant docetaxel, cisplatin and 5-fluororacil (TPF) followed by radiotherapy plus concomitant chemotherapy or cetuximab versus radiotherapy plus concomitant chemotherapy or cetuximab in patien...
    Medical condition: patients with locally advanced squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002128-33 Sponsor Protocol Number: 004-IRCC-10IIS-12 Start Date*: 2012-05-29
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO
    Full Title: Open-Label, Phase II Study of Trastuzumab in Combination with Lapatinib or Pertuzumab in Combination with Trastuzumab in Patients with HER2-positive Metastatic Colorectal Cancer: the HERACLES Trial...
    Medical condition: Metastatic colorectal carcinoma (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10010023 Colorectal neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000250-22 Sponsor Protocol Number: CVAY736X2201 Start Date*: 2014-04-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single dose, double-blind, placebo-controlled, parallel study to assess the pharmacodynamics, pharmacokinetics and safety and tolerability of VAY736 in patients with primary Sjögren’s syndrome
    Medical condition: Seropositive primary Sjögren’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005696-17 Sponsor Protocol Number: 1645-CI-058 Start Date*: 2013-06-18
    Sponsor Name:Instituto de Investigacion Sanitaria La Fe
    Full Title: Multicenter, randomized, blinded clinical study comparing early use of total body moderate hypothermia plus topiramate or placebo in asphyxiated newborn infants evolving to moderate-to-severe hypox...
    Medical condition: Asphyxiated newborn infants evolving to moderate-to-severe hypoxic ischemic encephalopathy
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001100-30 Sponsor Protocol Number: 1334hew16ct Start Date*: 2018-10-24
    Sponsor Name:Fachingen Heil- und Mineralbrunnen GmbH
    Full Title: Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placebo
    Medical condition: Efficacy and tolerability investigations of a healing water in symptomatic treatment of heartburn
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10019326 Heartburn LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004692-40 Sponsor Protocol Number: PPL20 Start Date*: 2021-03-30
    Sponsor Name:Dilafor AB
    Full Title: An Exploratory, Open label, Randomized, Parallel-Group, Pilot Study to evaluate Safety, Tolerability and Efficacy of daily, subcutaneous tafoxiparin treatment from the time of diagnosis for up to 4...
    Medical condition: Preeclampsia diagnosed at week 26-32 of gestation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10040444 Severe pre-eclampsia LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002715-38 Sponsor Protocol Number: APHP220775 Start Date*: 2023-03-20
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Immunogenicity and reactogenicity of the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi) compared to a bivalent mRNA vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech...
    Medical condition: Adults who received at least 3 doses of mRNA Covid 19 vaccine (BioNTech-Pfizer and/or Moderna), the last dose received at least 6 months prior to the inclusion in the trial.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003323-42 Sponsor Protocol Number: 29BRC20.0203 Start Date*: 2021-03-01
    Sponsor Name:CHRU de Brest
    Full Title: Diagnostic Performance of prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging for Pre-operative lymph Node assessment in intermediate and hig...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10036946 Prostatic cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001399-13 Sponsor Protocol Number: 69HCL19_0115 Start Date*: Information not available in EudraCT
    Sponsor Name:Hospices Civils de Lyon
    Full Title: MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL
    Medical condition: Patients with metastatic NRAS melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004557-24 Sponsor Protocol Number: UKM17_0056 Start Date*: 2019-07-29
    Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
    Full Title: Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 21:59:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA